Enanta Pharmaceuticals Inc.

45.97-3.06-6.24%Vol 275.49K1Y Perf 1.72%
May 18th, 2022 16:00 DELAYED
BID24.44 ASK51.00
Open47.73 Previous Close49.03
Pre-Market- After-Market37.88
 - -  -8.09 -17.60%
Target Price
81.50 
Analyst Rating
Moderate Buy 2.00
Potential %
77.29 
Finscreener Ranking
★+     42.45
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     51.05
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     40.03
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
9.09 
Earnings Rating
Strong Sell
Market Cap952.13M 
Earnings Date
9th May 2022
Alpha0.01 Standard Deviation0.14
Beta0.64 

Today's Price Range

44.8549.35

52W Range

40.37102.00

5 Year PE Ratio Range

-22.00138.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-4.80%
1 Month
-30.45%
3 Months
-23.85%
6 Months
-47.04%
1 Year
1.72%
3 Years
-45.53%
5 Years
52.98%
10 Years
-

TickerPriceChg.Chg.%
ENTA45.97-3.0600-6.24
AAPL140.82-8.4200-5.64
GOOG2 248.02-86.0100-3.69
MSFT254.08-12.1200-4.55
XOM90.65-1.4600-1.59
WFC42.11-1.6000-3.66
JNJ175.50-3.3200-1.86
FB192.24-10.3800-5.12
GE75.20-1.2000-1.57
JPM120.09-2.0900-1.71
Financial StrengthValueIndustryS&P 500US Markets
10.70
11.10
0.04
0.05
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-144.00
-140.40
-9.20
-81.96
RevenueValueIndustryS&P 500US Markets
91.56M
4.42
-24.51
2.06
Earnings HistoryEstimateReportedSurprise %
Q02 2022-1.43-1.63-13.99
Q01 2022-1.13-1.48-30.97
Q04 2021-1.31-1.226.87
Q03 2021-1.41-1.1915.60
Q02 2021-0.94-1.09-15.96
Q01 2021-0.82-0.4150.00
Q04 2020-0.92-0.5540.22
Q03 2020-0.73-0.712.74
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.45-57.61Negative
9/2022 QR-1.3914.20Positive
9/2022 FY-5.951.16Positive
9/2023 FY-4.72-1.29Negative
Next Report Date-
Estimated EPS Next Report-1.43
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume275.49K
Shares Outstanding20.71K
Shares Float16.01M
Trades Count6.11K
Dollar Volume12.75M
Avg. Volume235.82K
Avg. Weekly Volume281.67K
Avg. Monthly Volume211.32K
Avg. Quarterly Volume214.46K

Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) stock closed at 49.03 per share at the end of the most recent trading day (a 0.53% change compared to the prior day closing price) with a volume of 296.04K shares and market capitalization of 952.13M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 141 people. Enanta Pharmaceuticals Inc. CEO is Jay R. Luly.

The one-year performance of Enanta Pharmaceuticals Inc. stock is 1.72%, while year-to-date (YTD) performance is -34.43%. ENTA stock has a five-year performance of 52.98%. Its 52-week range is between 40.37 and 102, which gives ENTA stock a 52-week price range ratio of 9.09%

Enanta Pharmaceuticals Inc. currently has a PE ratio of -9.00, a price-to-book (PB) ratio of 2.88, a price-to-sale (PS) ratio of 11.03, a price to cashflow ratio of 154.60, a PEG ratio of 2.32, a ROA of -26.48%, a ROC of -27.38% and a ROE of -29.16%. The company’s profit margin is -81.96%, its EBITDA margin is -140.40%, and its revenue ttm is $91.56 Million , which makes it $4.42 revenue per share.

Of the last four earnings reports from Enanta Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.43 for the next earnings report. Enanta Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Enanta Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $81.5, which is +77.29% compared to the current price. The earnings rating for Enanta Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Enanta Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Enanta Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.71, ATR14 : 3.67, CCI20 : -120.20, Chaikin Money Flow : -0.27, MACD : -5.43, Money Flow Index : 14.76, ROC : -23.87, RSI : 25.87, STOCH (14,3) : 7.83, STOCH RSI : 0.25, UO : 31.71, Williams %R : -92.17), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Enanta Pharmaceuticals Inc. in the last 12-months were: Bruce L.A. Carter (Option Excercise at a value of $153 480), Bruce L.A. Carter (Sold 6 000 shares of value $406 970 ), Jay R. Luly (Option Excercise at a value of $236 883), Jay R. Luly (Sold 9 032 shares of value $533 396 ), Nathalie Adda (Option Excercise at a value of $6 247 105), Nathalie Adda (Sold 150 200 shares of value $10 659 139 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (50.00 %)
4 (50.00 %)
4 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (50.00 %)
4 (50.00 %)
4 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

CEO: Jay R. Luly

Telephone: +1 617 607-0800

Address: 500 Arsenal Street, Watertown 02472, MA, US

Number of employees: 141

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

64%36%

Bearish Bullish

51%49%

TipRanks News for ENTA

Tue, 10 May 2022 12:44 GMT Enanta Pharmaceuticals (ENTA) Receives a Hold from SVB Securities

- TipRanks. All rights reserved.

Tue, 10 May 2022 06:15 GMT Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Precision BioSciences (DTIL)

- TipRanks. All rights reserved.

Wed, 04 May 2022 12:51 GMT Enanta Pharmaceuticals (ENTA) Gets a Hold Rating from SVB Securities

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 12:56 GMT Enanta Pharmaceuticals (ENTA) Gets a Buy Rating from JMP Securities

- TipRanks. All rights reserved.

Thu, 07 Apr 2022 12:36 GMT Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Illumina (ILMN)

- TipRanks. All rights reserved.

Sat, 26 Feb 2022 17:09 GMT Enanta Pharmaceuticals (ENTA) Receives a Sell from Evercore ISI

- TipRanks. All rights reserved.

Sun, 13 Feb 2022 15:55 GMT Enanta Pharmaceuticals (ENTA) Receives a Buy from Robert W. Baird

- TipRanks. All rights reserved.

Fri, 11 Feb 2022 12:10 GMT Enanta Pharmaceuticals (ENTA) Receives a Hold from J.P. Morgan

- TipRanks. All rights reserved.

Fri, 07 Jan 2022 01:50 GMT Enanta Pharmaceuticals (ENTA) Receives a Hold from RBC Capital

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 05:35 GMT Analysts Top Healthcare Picks: Enanta Pharmaceuticals (ENTA), Crinetics Pharmaceuticals (CRNX)

- TipRanks. All rights reserved.

News

Stocktwits